COVID-19 vaccine development: milestones, lessons and prospects.
COVID-19 vaccine development: milestones, lessons and prospects.
复制标题
COVID-19疫苗开发：里程碑、教训和前景。
DOI：
10.1038/s41392-022-00996-y
复制
发表时间：
2022-05-03
影响因子：
39.3
通讯作者：
Fan H
中科院分区：
文献类型：
--
作者：
Li M;Wang H;Tian L;Pang Z;Yang Q;Huang T;Fan J;Song L;Tong Y;Fan H
随着SARS-CoV-2的不断变异和关注变异株（VOC）的出现，疫苗接种的实施至关重要。现有的SARS-CoV-2疫苗主要包括灭活疫苗、减毒活疫苗、病毒载体疫苗、蛋白亚单位疫苗、RNA疫苗、DNA疫苗和病毒样颗粒疫苗。病毒载体疫苗、蛋白亚单位疫苗和mRNA疫苗可诱导额外的细胞或体液免疫调节，包括Th细胞应答和生发中心应答，并形成相关记忆细胞，大大提高其效率。然而，一些病毒载体或mRNA疫苗可能与血小板减少症和心肌炎等并发症有关，这引发了人们对这些COVID-19疫苗安全性的担忧。在这里，我们系统地评估了COVID-19疫苗的安全性和有效性，包括可能的并发症以及对孕妇、老年人、免疫性疾病和获得性免疫缺陷综合征（艾滋病）患者、移植受者和癌症患者的不同影响。基于目前的分析，建议各国政府和相关机构继续推进疫苗免疫进程。同时，应特别关注疫苗的健康状况，及时处理并发症，研制疫苗，保障患者的生命健康。此外，可以考虑采取混合匹配疫苗接种、开发纳米颗粒疫苗等新疫苗以及优化免疫佐剂等措施，以提高疫苗的安全性和有效性。
With the constantly mutating of SARS-CoV-2 and the emergence of Variants of Concern (VOC), the implementation of vaccination is critically important. Existing SARS-CoV-2 vaccines mainly include inactivated, live attenuated, viral vector, protein subunit, RNA, DNA, and virus-like particle (VLP) vaccines. Viral vector vaccines, protein subunit vaccines, and mRNA vaccines may induce additional cellular or humoral immune regulations, including Th cell responses and germinal center responses, and form relevant memory cells, greatly improving their efficiency. However, some viral vector or mRNA vaccines may be associated with complications like thrombocytopenia and myocarditis, raising concerns about the safety of these COVID-19 vaccines. Here, we systemically assess the safety and efficacy of COVID-19 vaccines, including the possible complications and different effects on pregnant women, the elderly, people with immune diseases and acquired immunodeficiency syndrome (AIDS), transplant recipients, and cancer patients. Based on the current analysis, governments and relevant agencies are recommended to continue to advance the vaccine immunization process. Simultaneously, special attention should be paid to the health status of the vaccines, timely treatment of complications, vaccine development, and ensuring the lives and health of patients. In addition, available measures such as mix-and-match vaccination, developing new vaccines like nanoparticle vaccines, and optimizing immune adjuvant to improve vaccine safety and efficacy could be considered.
登录
查看更多内容
影响因子：
13.2
作者：
Ai J;Zhang H;Zhang Y;Lin K;Zhang Y;Wu J;Wan Y;Huang Y;Song J;Fu Z;Wang H;Guo J;Jiang N;Fan M;Zhou Y;Zhao Y;Zhang Q;Liu Q;Lv J;Li P;Qiu C;Zhang W
通讯作者：
Zhang W
DOI：
10.1056/nejmoa2119451
发表时间：
2022-04-21
期刊：
The New England journal of medicine
影响因子：
--
作者：
Andrews N;Stowe J;Kirsebom F;Toffa S;Rickeard T;Gallagher E;Gower C;Kall M;Groves N;O'Connell AM;Simons D;Blomquist PB;Zaidi A;Nash S;Iwani Binti Abdul Aziz N;Thelwall S;Dabrera G;Myers R;Amirthalingam G;Gharbia S;Barrett JC;Elson R;Ladhani SN;Ferguson N;Zambon M;Campbell CNJ;Brown K;Hopkins S;Chand M;Ramsay M;Lopez Bernal J
通讯作者：
Lopez Bernal J
影响因子：
9.2
作者：
Brocato RL;Kwilas SA;Kim RK;Zeng X;Principe LM;Smith JM;Hooper JW
通讯作者：
Hooper JW
DOI：
10.1016/s0140-6736(21)01420-3
发表时间：
2021-07-10
期刊：
Lancet (London, England)
影响因子：
--
作者：
Borobia AM;Carcas AJ;Pérez-Olmeda M;Castaño L;Bertran MJ;García-Pérez J;Campins M;Portolés A;González-Pérez M;García Morales MT;Arana-Arri E;Aldea M;Díez-Fuertes F;Fuentes I;Ascaso A;Lora D;Imaz-Ayo N;Barón-Mira LE;Agustí A;Pérez-Ingidua C;Gómez de la Cámara A;Arribas JR;Ochando J;Alcamí J;Belda-Iniesta C;Frías J;CombiVacS Study Group
通讯作者：
CombiVacS Study Group
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group